Semnur Pharmaceuticals, Inc., a biopharmaceutical company developing non-opioid solutions for pain management, has secured $100.0M in new funding. The capital infusion will support its efforts to address the widespread issue of back pain, a condition affecting most adults and a common reason for healthcare visits.
The company's primary focus is on non-opioid products for underserved patients with back pain, aiming to improve efficacy and safety. Its lead program, SP-102 (SEMDEXAâ„¢), is a non-opioid injectable corticosteroid gel formulation for moderate to severe chronic radicular pain/sciatica, designed as an alternative in a market where opioid prescriptions for back pain remain high.
